Phase 1bData readout

CAN-3110

Solid tumor/s, Cancer, Glioma

CADLCandel Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: CAN-3110
Development stage: Phase 1b
Event type: Data readout
Indication: Solid tumor/s, Cancer, Glioma

Research summary

What is being tracked?

This catalyst tracks a Phase 1b data readout for CAN-3110 in Solid tumor/s, Cancer, Glioma. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- Linoserpaturev IND clearance and Q4 2026 arm C mOS update reiterated. 08/13/26:- Phase 2 planning advanced for rGBM. Arm C long-term survival data will be presented in Q4 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source